{
    "nct_id": "NCT05501899",
    "official_title": "Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia",
    "inclusion_criteria": "* Patients aged 5 to < 30 years\n* Newly diagnosed with ALL designated as NCI high-risk (HR) ALL\n* Treatment for ALL to be according to a Children's Oncology Group (COG) treatment protocol (on study or according to study)\n* Ability to take oral medications and willing to adhere to the levocarnitine regimen\nHealthy volunteers allowed\nMust have minimum age of 5 Years\nMust have maximum age of 29 Years",
    "exclusion_criteria": "* Known allergic reaction to levocarnitine or its components\n* Presence of severely compromised renal function or end-stage renal disease\n* Pregnancy or lactation\n* Warfarin therapy\n* History of seizures prior to ALL diagnosis\n* Known inborn error of metabolism",
    "miscellaneous_criteria": ""
}